X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (401) 401
Paper (161) 161
Publication (116) 116
Report (6) 6
Book Review (4) 4
Data Set (1) 1
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
experimental results (174) 174
experiment (173) 173
cms (172) 172
cern lhc coll (170) 170
physics (156) 156
particle physics (148) 148
high energy physics - experiment (147) 147
p p: scattering (130) 130
8000 gev-cms (129) 129
physics - high energy physics - experiment (128) 128
high energy physics (121) 121
p p: colliding beams (111) 111
physics of elementary particles and fields (107) 107
scattering [p p] (89) 89
phenomenology (83) 83
particle physics - experiment (80) 80
colliding beams [p p] (73) 73
nuclear experiment (47) 47
physics, particles & fields (42) 42
background (36) 36
index medicus (35) 35
[phys.hexp]physics [physics]/high energy physics - experiment [hep-ex] (32) 32
humans (31) 31
rapidity dependence (30) 30
supersymmetry (29) 29
hadron-hadron scattering (28) 28
nuclear and high energy physics (28) 28
transverse momentum dependence (26) 26
cern lab (25) 25
data analysis method (24) 24
astronomy & astrophysics (23) 23
kinematics (23) 23
jet: bottom (21) 21
higgs particle: hadroproduction (20) 20
jet: transverse momentum (20) 20
quantum chromodynamics: perturbation theory (20) 20
differential cross section: measured (18) 18
physics and astronomy (18) 18
animals (17) 17
astrophysics (17) 17
collisions (17) 17
final state:jet lepton (17) 17
high energy astrophysical phenomena (16) 16
physics, nuclear (16) 16
114 physical sciences (15) 15
7000 gev-cms (15) 15
channel cross section: upper limit (15) 15
immunology (15) 15
nuclear physics (15) 15
top: pair production (15) 15
transverse momentum [jet] (15) 15
transverse momentum: missing-energy (15) 15
z0: leptonic decay (15) 15
7000 gev-cms8000 gev-cms (14) 14
bottom [jet] (14) 14
sensitivity (14) 14
transverse energy: missing-energy (14) 14
[ phys.hexp ] physics [physics]/high energy physics - experiment [hep-ex] (13) 13
cell biology (13) 13
elementary particles, quantum field theory (13) 13
final state:jet dilepton (13) 13
hadroproduction [higgs particle] (13) 13
jet lepton (13) 13
jet: multiplicity (13) 13
large hadron collider (13) 13
mass dependence (13) 13
missing-energy [transverse energy] (13) 13
numerical calculations: monte carlo (13) 13
parton: distribution function (13) 13
quantum field theories, string theory (13) 13
research (13) 13
cross section: branching ratio: upper limit (12) 12
engineering (12) 12
lead (12) 12
lymphocytes (12) 12
perturbation theory [quantum chromodynamics] (12) 12
z0: associated production (12) 12
instrumentation and detectors (11) 11
luminosity (11) 11
measured [differential cross section] (11) 11
new physics: search for (11) 11
quantum chromodynamics (11) 11
searching (11) 11
w: leptonic decay (11) 11
analysis (10) 10
differential cross section (10) 10
higgs particle: mass (10) 10
higher-order: 1 (10) 10
jet dilepton (10) 10
leptonic decay [z0] (10) 10
male (10) 10
performance (10) 10
rapidity (10) 10
t cell receptors (10) 10
topology (10) 10
track data analysis (10) 10
upper limit [channel cross section] (10) 10
associated production [z0] (9) 9
bottom: particle identification (9) 9
channel cross section: measured (9) 9
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 10/2016, Volume 113, Issue 42, pp. 11919 - 11924
Immune checkpoint therapies, such as ipilimumab, induce dramatic antitumor responses in a subset of patients with advanced malignancies, but they may also... 
Toxicities | T cells | Prostate cancer | CD8 | Ipilimumab | CTLA-4 BLOCKADE | PD-1 BLOCKADE | MULTIDISCIPLINARY SCIENCES | toxicities | DOCETAXEL | CHEMOTHERAPY | LUNG-CANCER | prostate cancer | ADVANCED MELANOMA | ipilimumab | PROSTATE-CANCER | PHASE-3 TRIAL | DOUBLE-BLIND | NIVOLUMAB | T-Lymphocyte Subsets - immunology | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Ipilimumab - therapeutic use | CD8-Positive T-Lymphocytes - metabolism | Prostatic Neoplasms - drug therapy | Severity of Illness Index | Prostatic Neoplasms - pathology | Disease Susceptibility | Drug-Related Side Effects and Adverse Reactions - etiology | Treatment Outcome | Ipilimumab - adverse effects | Antineoplastic Agents, Immunological - adverse effects | Antineoplastic Agents, Immunological - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | T-Lymphocyte Subsets - metabolism | Biomarkers | Lymphocyte Count | Prostatic Neoplasms - complications | CD8-Positive T-Lymphocytes - immunology | Clonal Evolution - immunology | Drug-Related Side Effects and Adverse Reactions - diagnosis | Clinical Trials, Phase II as Topic | Drugs | Complications and side effects | Cell research | CD8 lymphocytes | Physiological aspects | Adverse and side effects | Dosage and administration | Research | Health aspects | Biological Sciences
Journal Article
Journal Article
Nature Genetics, ISSN 1061-4036, 05/2017, Volume 49, Issue 5, pp. 659 - 665
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 09/2017, Volume 23, Issue 18, pp. 5514 - 5526
Purpose: Radiotherapy is a highly effective anticancer treatment forming part of the standard of care for the majority of patients, but local and distal... 
BREAST-CANCER | RESPONSES | ANTICANCER CHEMOTHERAPY | ONCOLOGY | LOCAL RADIATION | FTY720 | TUMOR | MICE | RADIOTHERAPY | DIFFERENTIATION | ANTIGEN | Neoplasms - metabolism | T-Lymphocyte Subsets - immunology | Humans | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Neoplasms - therapy | T-Lymphocyte Subsets - drug effects | Lymphocytes, Tumor-Infiltrating - metabolism | Disease Models, Animal | Antineoplastic Agents, Hormonal - pharmacology | Cytokines - metabolism | Programmed Cell Death 1 Receptor - metabolism | Survival Rate | T-Lymphocyte Subsets - radiation effects | Combined Modality Therapy | Lymphocytes, Tumor-Infiltrating - drug effects | Radiotherapy | Xenograft Model Antitumor Assays | Animals | Neoplasms - immunology | T-Lymphocyte Subsets - metabolism | Cell Line, Tumor | Mice | Receptors, Antigen, T-Cell, alpha-beta - metabolism | Neoplasms - pathology | Lymphocytes, Tumor-Infiltrating - radiation effects | Lymphocytes, Tumor-Infiltrating - immunology | Flow cytometry | Immune response | PD-1 protein | Trafficking | Radiation | Immune clearance | Lymphocytes T | T cell receptors | Radiation therapy | Immunity | Metastases | Anticancer properties | T-cell receptor | Cytometry | Immunogenicity | Experimental design | Lymphocytes | PD-L1 protein | Monoclonal antibodies | Infiltration | Lesions | Cancer
Journal Article
PLoS Medicine, ISSN 1549-1277, 05/2017, Volume 14, Issue 5, p. e1002309
Background Inhibition of programmed death-ligand 1 (PD-L1) with atezolizumab can induce durable clinical benefit (DCB) in patients with metastatic urothelial... 
METASTATIC MELANOMA | CTLA-4 BLOCKADE | CELLS | MEDICINE, GENERAL & INTERNAL | REPAIR | THERAPY | DYNAMICS | CARCINOMA | Carcinoma - immunology | Antibodies, Monoclonal - pharmacology | Humans | Middle Aged | Urologic Neoplasms - etiology | Carcinoma - prevention & control | Male | B7-H1 Antigen - immunology | Carcinoma - etiology | Urothelium - pathology | Urologic Neoplasms - immunology | Exome - genetics | B7-H1 Antigen - antagonists & inhibitors | Sequence Analysis, RNA | Aged, 80 and over | Female | Urologic Neoplasms - prevention & control | Aged | Antineoplastic Agents - pharmacology | Receptors, Antigen, T-Cell - genetics | Care and treatment | Research | Cancer | Membrane proteins | Urothelium | Therapy | Correlation | Science | Staining | Lymphocytes T | Metastasis | Cancer therapies | Blood | Clinical outcomes | Loads (forces) | Gene sequencing | Metastases | T-cell receptor | Missense mutation | Lymphocytes | Data integration | Peripheral blood | Interrogation | Genetics | Inhibition | Pretreatment | Urothelial carcinoma | Immune system | Medical research | Urothelial cancer | Load | Integration | Immune response | Cell survival | Mortality | Melanoma | Durability | T cell receptors | Ribonucleic acid--RNA | Patients | Survival | Medicine | Chemotherapy | Sensitivity | Immune checkpoint | Medical prognosis | PD-L1 protein | Death | Infiltration | Mutation | Tumors | Apoptosis | RNA | Ribonucleic acid
Journal Article
Cancer, ISSN 0008-543X, 09/2017, Volume 123, Issue 17, pp. 3291 - 3304
BACKGROUND Patients with metastatic sarcomas have poor outcomes and although the disease may be amenable to immunotherapies, information regarding the... 
leiomyosarcoma | sarcoma | pleomorphic | programmed death‐ligand 1 (PD‐L1) | T‐cell receptors | immunotherapy | liposarcoma | gene expression | programmed cell death protein (PD‐1) | T-cell receptors | programmed cell death protein (PD-1) | programmed death-ligand 1 (PD-L1) | NY-ESO-1 | PAZOPANIB | DOXORUBICIN | CANCER | TRIAL | ONCOLOGY | EUROPEAN-ORGANIZATION | BLOCKADE | LYMPHOCYTES | Immunohistochemistry | Prognosis | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Male | Sarcoma - therapy | Young Adult | Neoplasm Invasiveness - pathology | Sarcoma - mortality | Aged, 80 and over | Adult | Female | Clone Cells | Retrospective Studies | Sarcoma - genetics | Soft Tissue Neoplasms - genetics | Databases, Factual | Soft Tissue Neoplasms - therapy | Soft Tissue Neoplasms - mortality | Combined Modality Therapy | Sarcoma - pathology | Disease-Free Survival | Analysis of Variance | T-Lymphocytes - cytology | Soft Tissue Neoplasms - pathology | Survival Analysis | T-Lymphocytes - immunology | Aged | Biopsy, Needle | Neoplasm Staging | Programmed Cell Death 1 Receptor - genetics | Cluster Analysis | Cohort Studies | Care and treatment | Sarcoma | Cell death | Analysis | Research | Diagnosis | Gene expression | PD-1 protein | Identification methods | Lymphocytes T | Paraffin | Formaldehyde | Metastases | Gene sequencing | T-cell receptor | Immunotherapy | Immune system | Antigen presentation | Antigens | Immune response | Synovial sarcoma | Mortality | Soft tissue sarcoma | Autoantigens | Inflammation | T cell receptors | Patients | Immune checkpoint | Immunogenicity | PD-L1 protein | Liposarcoma | Ligands | Infiltration | Cancer | Tumors | Apoptosis | Original
Journal Article
Journal of Immunology, ISSN 0022-1767, 02/2017, Volume 198, Issue 4, pp. 1740 - 1747
Journal Article
Cellular Microbiology, ISSN 1462-5814, 05/2014, Volume 16, Issue 5, pp. 602 - 611
Journal Article
Journal of Clinical Pathology, ISSN 0021-9746, 09/2018, Volume 71, Issue 9, pp. 814 - 820
AimsSubstantial clinicopathological overlap exists between cutaneous T-cell lymphoma (CTCL) and benign conditions, leading to diagnostic difficulties. We... 
haematopathology | dermatopathology | molecular pathology | lymphoma | TCRG | EORTC | TISSUE | MYCOSIS-FUNGOIDES | CLASSIFICATION | PATHOLOGY | CANCER | DISEASE | GENE REARRANGEMENT | CLONALITY | PCR | Flow cytometry | Psoriasis | Lymphocytes | Capillary electrophoresis | T cell receptors | Skin | Lymphomas | Fungal infections | Medical diagnosis | Dermatitis | Deoxyribonucleic acid--DNA | Cancer
Journal Article